Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
Public ClinicalTrials.gov record NCT04675151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Pilocarpine Eye Drops in Subjects With Presbyopia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia
Study identification
- NCT ID
- NCT04675151
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Interventions
- Phentolamine Ophthalmic Solution 0.75% Drug
- Pilocarpine Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 40 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2021 (Actual)
- Primary completion
- May 17, 2021 (Actual)
- Completion
- Jun 30, 2021 (Actual)
- Last update posted
- Oct 10, 2025
2021
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site 12 | Laguna Hills | California | 92653 | — |
| Clinical Site 6 | Newport Beach | California | 92663 | — |
| Clinical Site 13 | Crystal River | Florida | 34461 | — |
| Clinical Site 5 | Longwood | Florida | 32779 | — |
| Clinical Site 11 | Maitland | Florida | 32751 | — |
| Clinical Site 8 | Sarasota | Florida | 34239 | — |
| Clinical Site 10 | Roswell | Georgia | 30041 | — |
| Clinical Site 3 | Pittsburg | Kansas | 66762 | — |
| Clinical Site 18 | St Louis | Missouri | 63101 | — |
| Clinical Site 16 | Poughkeepsie | New York | 12603 | — |
| Clinical Site 14 | Fargo | North Dakota | 58103 | — |
| Clinical Site 2 | Athens | Ohio | 45701 | — |
| Clinical Site 9 | Cincinnati | Ohio | 45242 | — |
| Clinical Site 7 | Cleveland | Ohio | 44115 | — |
| Clinical Site 15 | Powell | Ohio | 43065 | — |
| Clinical Site 4 | Warwick | Rhode Island | 02888 | — |
| Clinical Site 1 | Memphis | Tennessee | 38119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04675151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 10, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04675151 live on ClinicalTrials.gov.